Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) Net Income towards Common Stockholders (2018 - 2025)

BioNexus Gene Lab's Net Income towards Common Stockholders history spans 8 years, with the latest figure at -$1.0 million for Q4 2025.

  • Quarterly results put Net Income towards Common Stockholders at -$1.0 million for Q4 2025, down 197.46% from a year ago — trailing twelve months through Dec 2025 was -$3.0 million (down 86.73% YoY), and the annual figure for FY2025 was -$3.0 million, down 86.73%.
  • Net Income towards Common Stockholders for Q4 2025 was -$1.0 million at BioNexus Gene Lab, down from -$708991.0 in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $351515.0 in Q4 2023 to a low of -$2.6 million in Q3 2023.
  • The 5-year median for Net Income towards Common Stockholders is -$121209.5 (2022), against an average of -$337135.0.
  • Peak annual rise in Net Income towards Common Stockholders hit 329.64% in 2023, while the deepest fall reached 3271.0% in 2023.
  • Year by year, Net Income towards Common Stockholders stood at $115979.0 in 2021, then plummeted by 231.98% to -$153071.0 in 2022, then skyrocketed by 329.64% to $351515.0 in 2023, then crashed by 199.09% to -$348319.0 in 2024, then plummeted by 197.46% to -$1.0 million in 2025.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods came in at -$1.0 million, -$708991.0, and -$616172.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.